Presentations 2004
11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2004
1 Predictors of Hypertension and Changes in Blood Pressure in HIV-infected Patients in the D:A:D study. R Thiebaut, W El-Sadr, N Friis-Møller, M Rickenbach, P Reiss, A D´Arminio Monforte, L Morfeldt, C Pardier, O Kirk, S De Wit, G Calvo, M Law, C Sabin, J D Lundgren and D:A:D Study Group.
(DAD 75)
2 Final Week 48 Analysis of a Phase 4, Randomised, Open-label, Multi-center Trial to Evaluate Safety and Efficacy of Continued Lamivudine Twice Daily Versus Discontinuation of Lamivudine in HIV-1-infected Adults with Virological Failure on ongoing Combination Treatments Containing Lamivudine: The COLATE Trial. U Dragsted, Z Fox, L Mathiesen, C Katlama, M Youle, J Gerstoft, J N Bruun and J D Lundgren for the COLATE Trial Group
(COLATE 549)
3 Time to Triple Drug Class Failure after Initiation of HAART. A Mocroft, B Ledergerber, J P Viard, S Staszewski, M Murphy, A Chiesi, A Horban, A B Hansen, A N Phillps, J D Lundgren and the EuroSIDA Study Group.
(EuroSIDA 554)
4 The Role of Genetic Polymorphisms of the MDR1 Gene in the MaxCmin1 Study. A Owen, Z Fox, L Almond, U Bak Dragsted, D Back, M Youle, J Lundgren, S Khoo, and the MaxCmin1 Steering Commitee.
(MaxCmin1 619b)
5 Lipid Profiles of Patients Enrolled in the MaxCmin2 Trial: A Randomised, Open-label Multi-centre Comparative Trial Evaluating the Safety and Efficacy of Lopinavir/ Ritonavir (400/100 mg twice daily) vs Saquinavir/Ritonavir SQV/r (1000/100 mg twice daily). S L Walmsley, J Benetucci, A Brutus, N Clumeck, U B Dragsted, B Gazzard, N Obel, P Vernazza, Z Fox, J D Lundgren and on behalf of the MaxCmin2 Trial Group.
(MaxCmin2 720)
6 Cardio- and Cerebrovascular Events and Predicted Rates of Myocardial Infarction in the D:A:D study. M G Law, A D´Arminio Monforte, N Friis-Møller, R Weber, W El-Sadr, P Reiss, F Dabis, L Morfledt, S De Wit, C Pradier, G Calvo, O Kirk, C Sabin, A N Phillips and JD Lundgren.
(DAD 737)
7 Hepatitis B and Hepatitis C in the EuroSIDA Cohort: Prevalence and Effect on Mortality, AIDS Progression and Response to HAART. J Rockstroh, D Konopnicki, V Soriano, O Kirk, F Antunes, B Knysz, C Tural, S De Wit, A Mocroft, J Lundgren and the EuroSIDA Study Group.
(EuroSIDA 799)
XV International AIDS Conference, July 2004, Bangkok
1 Estimation of clinical events in the control arm of the ESPRIT trial based on data from an observational database. J D Lundgren
(ESPRIT B10257) abstract
2 Predictors of the CD4 count response during the first 8 months of follow-up in the IL-2 arm of ESPRIT. K Ruxrungtham, Z V Fox, F Antunes, J D Bebchuk, R T Davey, B Gazzard, N G Klimas, A M Labriola, M H Losso, J D Neaton, S Staszewski, L Weiss, A N Phillips, J D Lundgren.
(ESPRIT WeOrB1288) abstract
3 Comparison of observed clinical event rates in the ESPRIT trial with projections from the EuroSIDA study. J D Lundgren, A Mocroft, J Bebchuck, S. Staszewski, F Antunes, B Knysz, M Law, A N Phillips, J Neaton.
(ESPRIT/EuroSIDA WePeB5685) abstract
44th ICAAC, October 2004, Washington
1 Comparison of 6 HIV-1 genotypic resistance algorithms for predicting viral load change to week 4. Z Fox, J Gerstoft, UB Dragsted, AN Phillips, P Cahn, J Gatell, JD Lundgren
(MaxCmin2 H-185) abstract
6th International Conference on Adverse Drug Reactions and Lipodystrophy in HIV, October 2004, Washington
1 Association of risk toxicity with drug levels of saquinavir boosted with ritonavir in the MaxCmin 1 & 2 trials. JD Lundgren, Z Fox, US Justesen, S Warmsley, M Youle, P Vernazza, J Gerstoft, M Losso, and UB Dragsted on behalf of the MaxCmin trial groups.
(MaxCmin 1&2 79)
2 Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen. A Mocroft, AN Phillips, V Soriano, J Rockstroh, A Blaxhult, C Katlama, A Boron-Kaczmarska, L Viksna, O Kirk, JD Lundgren for the EuroSIDA study group.
(EuroSIDA 74)
7th International Congress on Drug Therapy in HIV Infection, November 2004 Glasgow
1 Interruption/stopping HAART and risk of clinical disease progression to AIDS/death in EuroSIDA. C Holkmann-Olsen, A Mocroft, S Vella, A Blaxhult, N Clumeck, O Kirk, M Fisher, C Katlama, A Phillips, J Lundgren
(EuroSIDA P5)
2 What is the status of IL-2? J D Lundgren.
(PL8.1)
3 Why do patients stop antiretrovirals used as part of an initial HAART regimen? Results from the EuroSIDA study group. A Mocroft, A Phillips, V Soriano, J Rockstroh, A Blaxhult, C Katlama, A Boron-Kaczmarska, L Viksna, O Kirk, J Lundgren
(EuroSIDA PL14.1)
4 HIV-patients across Europe: regional differences in patient characteristics. D Podlekareva, W Bannister, L Viksna, A Mocroft, B Knysz, P Reiss, N Chentsova, D Duiculescu, JD Lundgren, O Kirk, The EuroSIDA Study.
(EuroSIDA P67)
Updated: 13 Dec 2005